Posts Tagged ‘acelrx’
AcelRx Announces Successful Completion Of End-of-Phase 2 Meeting On ARX-01, Sufentanil NanoTab PCA System For Post-Operative Pain Management
AcelRx Pharmaceuticals, Inc announced that it has successfully completed an End-of-Phase 2 meeting with the FDA for ARX-01, a drug/device combination product based on the company’s proprietary NanoTab(TM) dosage form, which enables delivery of sufentanil by the non-invasive oral transmucosal (sublingual) route. ARX-01 offers a non-invasive alternative to intravenous patient-controlled analgesia (IV PCA) for the management of acute post-operative pain in the hospital setting.
AcelRx Announces Positive Results From A Phase 2 Study Of ARX-03, A Sufentanil/Triazolam NanoTab For Procedural Sedation, Anxiolysis & Analgesia
AcelRx Pharmaceuticals, Inc. announced positive results from a Phase 2 clinical trial of ARX-03, a proprietary sublingual dosage form combining an opioid, sufentanil, with a benzodiazepine, triazolam. ARX-03 is designed to address the current unmet need for a non-invasive product to provide mild sedation, anxiolysis and analgesia with rapid onset of action for the increasing number of painful and anxiety-producing office-based procedures.
AcelRx Announces Perfect Performance Of Handheld Component Of ARX-01 Sufentanil NanoTab PCA System In A Phase 2 Study
AcelRx Pharmaceuticals, Inc. announced positive results from its first Phase 2 clinical study evaluating the functionality of the handheld device component of its ARX-01 Sufentanil NanoTab(TM) PCA System for management of acute post-operative pain in patients requiring opioid analgesia during hospitalization. Patients reliably self-administered sufentanil NanoTabs repeatedly over the 12-hour study without any ARX-01 System failures or dosing errors of any kind.
AcelRx Announces Positive Phase 2 Results From A Study Of ARX-01 Sufentanil NanoTabs In Treating Post-Operative Pain
AcelRx Pharmaceuticals, Inc. announced positive results from the second Phase 2 clinical study evaluating the safety and efficacy of its ARX-01 Sufentanil NanoTabs(TM) for the management of acute post-operative pain in patients requiring opioid analgesia during hospitalization.
AcelRx Announces Initiation Of Phase 2 Cancer Breakthrough Pain Program
AcelRx Pharmaceuticals, Inc. announced that it has initiated a Phase 2 clinical trial of ARX-02, a proprietary sublingual sufentanil NanoTab(TM) product candidate for cancer breakthrough pain control. The primary objective of this multicenter, randomized, placebo-controlled, crossover study is assessment of safety, tolerability and efficacy of ARX-02 relative to placebo in cancer patients experiencing episodic breakthrough pain.
Rx Drug Compare
Translator
By N2H